Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?

38Citations
Citations of this article
64Readers
Mendeley users who have this article in their library.

Abstract

Purpose of reviewThere are currently several available biologics for rheumatoid arthritis (RA) with similar efficacy in most trials. A major consideration therefore in choosing a biologic, continues to be safety concerns such as infection. Considerable advances have been made in the understanding of biologic safety on a population level; however, how close are we to stratifying risk for individual patients? This review discusses evidence published in the last year, with reference to key previous literature.Recent findingsComparative safety of biologics has been studied in observational cohorts, with a possible increased risk of serious infection in tocilizumab-treated patients compared with etanercept. Rheumatoid arthritis patients on biologics are often on concomitant medications such as steroids and opioids, and the advances in relation to infection are summarized. Pharmacological biomarkers and optimizing existing risk prediction scores may allow better future risk stratification.SummaryImproved quantification of personalized benefit:harms would allow better-informed decisions, reduction of infection-associated morbidity as well as direct/indirect costs associated with biologics. Although advances have been made to better understand and predict risk, future studies are likely to require a range of novel data sources and methodologies for the goal of precision medicine to be truly realized.

References Powered by Scopus

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

2875Citations
N/AReaders
Get full text

Adverse effects of biologics: A network meta-analysis and Cochrane overview

853Citations
N/AReaders
Get full text

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)

595Citations
N/AReaders
Get full text

Cited by Powered by Scopus

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

2071Citations
N/AReaders
Get full text

Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals

105Citations
N/AReaders
Get full text

Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy

101Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Jani, M., Barton, A., & Hyrich, K. (2019, May 1). Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification? Current Opinion in Rheumatology. Lippincott Williams and Wilkins. https://doi.org/10.1097/BOR.0000000000000598

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 24

77%

Researcher 4

13%

Professor / Associate Prof. 2

6%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 30

77%

Pharmacology, Toxicology and Pharmaceut... 5

13%

Biochemistry, Genetics and Molecular Bi... 3

8%

Nursing and Health Professions 1

3%

Save time finding and organizing research with Mendeley

Sign up for free